Circulating tumor cells: mechanisms and clinical significance in colorectal cancer metastasis [0.03%]
循环肿瘤细胞在结直肠癌转移中的机制和临床意义
Xuanyu Ren,Mei Song,Xianzhi Liu et al.
Xuanyu Ren et al.
Tumors are a major global health problem. As economic development and material standards increase, the incidence and mortality of digestive system tumors have shown an overall rising trend. Among them, colorectal cancer (CRC) is the third m...
A circRNA promotes esophageal squamous cell carcinoma progression by inhibiting TRIM25-mediated degradation of IGF2BP family members [0.03%]
一个圆环状RNA通过抑制TRIM25介导的IGF2BP家族成员降解促进食管鳞癌进展
Shuangyan Tan,Yue Ming,Jiawei Guo et al.
Shuangyan Tan et al.
Background: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis and limited treatment options. While circular RNAs (circRNAs) are frequently dysregulated in ESCC, their function...
Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy [0.03%]
重新编程细胞衰老和衰老时钟以用于先进的癌症免疫治疗
Huiting Yang,Dong Liu,Liewang Qiu et al.
Huiting Yang et al.
Cellular senescence has gradually been recognized as a key process, which not only inhibits the occurrence of early tumors but also promotes advanced malignant progression through secretory and immunomodulatory functions. Initially, cellula...
Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy [0.03%]
重新编程细胞衰老和衰老时钟用于先进的癌症免疫治疗
Huiting Yang,Dong Liu,Liewang Qiu et al.
Huiting Yang et al.
Cellular senescence has gradually been recognized as a key process, which not only inhibits the occurrence of early tumors but also promotes advanced malignant progression through secretory and immunomodulatory functions. Initially, cellula...
Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study [0.03%]
TAS-102联合苏尼替尼三线及以上治疗胰腺癌的疗效和安全性：一项前瞻性、单中心及生物标志物探索性Ⅱ期研究
Yunxin Lu,Qingguang Lin,Yongxin Mo et al.
Yunxin Lu et al.
Background: Metastatic pancreatic cancer (mPC) has a dismal prognosis, with first line systemic therapy relying primarily on FOLFIRINOX (5FU/irinotecan/oxaliplatin) or AG (Gemcitabine/Nab-Paclitaxel). Therapeutic options ...
Clinical Trial
Molecular cancer. 2025 Oct 2;24(1):235. DOI:10.1186/s12943-025-02437-0 2025
Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study [0.03%]
TAS-102联合苏尼替尼治疗三线及以上转移性胰腺导管腺癌的前瞻性、单中心、探索生物标志物的Ⅱ期临床研究
Yunxin Lu,Qingguang Lin,Yongxin Mo et al.
Yunxin Lu et al.
Background: Metastatic pancreatic cancer (mPC) has a dismal prognosis, with first line systemic therapy relying primarily on FOLFIRINOX (5FU/irinotecan/oxaliplatin) or AG (Gemcitabine/Nab-Paclitaxel). Therapeutic options ...
Clinical Trial
Molecular cancer. 2025 Oct 2;24(1):235. DOI:10.1186/s12943-025-02437-0 2025
Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization [0.03%]
Hsa_circ_0038737通过IGF2BP3介导的DNPH1 mRNA稳定促进PARPi抵抗去势抵抗性前列腺癌
Zhongyuan Wang,Qintao Ge,Aihetaimujiang Anwaier et al.
Zhongyuan Wang et al.
Background: Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) poses a major challenge to therapeutic efficacy in castration-resistant prostate cancer (CRPC). Although circular RNAs (circRNAs) have emerged as c...
Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization [0.03%]
Hsa_circ_0038737通过IGF2BP3介导的DNPH1 mRNA稳定促进PARP抑制剂耐药性前列腺癌的发展
Zhongyuan Wang,Qintao Ge,Aihetaimujiang Anwaier et al.
Zhongyuan Wang et al.
Background: Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) poses a major challenge to therapeutic efficacy in castration-resistant prostate cancer (CRPC). Although circular RNAs (circRNAs) have emerged as c...
P23 acts as a negative regulator of ferroptosis in NSCLC by blocking GPX4 degradation via chaperone-mediated autophagy [0.03%]
P23通过分子伴侣介导的自噬抑制GPX4降解从而作为NSCLC铁死亡的负调控因子
Junlin Chen,Yulin Peng,Meirong Zhou et al.
Junlin Chen et al.
Ferroptosis has been identified as a tumor-inhibiting event in a variety of cancers; however, its molecular basis in non-small cell lung cancer (NSCLC) has not been completely elucidated. Notably, glutathione peroxidase 4 (GPX4) plays a cru...
P23 acts as a negative regulator of ferroptosis in NSCLC by blocking GPX4 degradation via chaperone-mediated autophagy [0.03%]
P23通过自噬途径阻断GPX4降解在非小细胞肺癌中铁死亡的负调控作用
Junlin Chen,Yulin Peng,Meirong Zhou et al.
Junlin Chen et al.
Ferroptosis has been identified as a tumor-inhibiting event in a variety of cancers; however, its molecular basis in non-small cell lung cancer (NSCLC) has not been completely elucidated. Notably, glutathione peroxidase 4 (GPX4) plays a cru...